Arcellx shows strong safety data for multiple myeloma treatment

Arcellx has reported strong safety data for its treatment of multiple myeloma, which is seen as a positive development. This safety profile is notable when compared to leading therapies like Carvykti from Legend Biotech. Despite the promising safety data, there are lingering doubts about the overall effectiveness of Arcellx's treatment. Analysts are closely monitoring its performance in the market. The company continues to attract attention in the competitive landscape of multiple myeloma treatments, but questions remain about its long-term viability.